Ks. Srivenugopal et F. Aliosman, ACTIVITY AND DISTRIBUTION OF THE CYSTEINE PRODRUG ACTIVATING ENZYME, 5-OXO-L-PROLINASE, IN HUMAN NORMAL AND TUMOR-TISSUES, Cancer letters, 117(1), 1997, pp. 105-111
5-Oxo-L-prolinase (OPase), a key enzyme of the gamma-glutamyl cycle, h
as the ability to metabolize L-2-oxothiazolidine-4-carboxylic acid (OT
C) to cysteine, and thereby increase intracellular glutathione (GSH) l
evels. This strategy of GSH elevation can be potentially exploited to
reduce normal tissue toxicity of anticancer agents, provided that suff
icient differences exist in OPase levels between normal and malignant
tissues. in this study, therefore, we quantitated OPase activity in pr
imary specimens of matched and unmatched human normal and tumor (lung,
breast, kidney, colon and ovary) tissues using a newly developed non-
radioactive OPase assay, based on the production of cysteine from OTC.
The rank order of OPase activity in extracts of 24 normal tissues exa
mined was kidney > lung, breast and colon > ovary. OPase activity was
present in all 37 tumor samples, but at variable levels. Tumor OPase l
evels were generally equivalent to those in their normal tissue counte
rparts, with the notable exception of Wilms' tumors, which had markedl
y lower levels than normal kidney (P < 0.02). However, when 14 matched
tumor and adjacent normal tissues were compared, OPase levels were si
gnificantly higher in normal specimens than tumors for individual pati
ents (P < 0.005). These higher normal tissue/tumor OPase ratios sugges
t that OTC may be useful in decreasing normal tissue toxicity, at leas
t, for some tissues during cancer therapy. (C) 1997 Elsevier Science I
reland Ltd.